‡Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand.
Biosci Rep. 2013 Nov 5;33(6):e00079. doi: 10.1042/BSR20130075.
NTT (N-terminal tags) on the catalytic (p110) sub-unit of PI 3-K (phosphoinositol 3-kinase) have previously been shown to increase cell signalling and oncogenic transformation. Here we test the impact of an NT (N-terminal) His-tag on in vitro lipid and protein kinase activity of all class-1 PI 3-K isoforms and two representative oncogenic mutant forms (E545K and H1047R), in order to elucidate the mechanisms behind this elevated signalling and transformation observed in vivo. Our results show that an NT His-tag has no impact on lipid kinase activity as measured by enzyme titration, kinetics and inhibitor susceptibility. Conversely, the NT His-tag did result in a differential effect on protein kinase activity, further potentiating the elevated protein kinase activity of both the helical domain and catalytic domain oncogenic mutants with relation to p110 phosphorylation. All other isoforms also showed elevated p110 phosphorylation (although not statistically significant). We conclude that the previously reported increase in cell signalling and oncogenic-like transformation in response to p110 NTT is not mediated via an increase in the lipid kinase activity of PI 3-K, but may be mediated by increased p110 autophosphorylation and/or other, as yet unidentified, intracellular protein/protein interactions. We further observe that tagged recombinant protein is suitable for use in in vitro lipid kinase screens to identify PI 3-K inhibitors; however, we recommend that in vivo (including intracellular) experiments and investigations into the protein kinase activity of PI 3-K should be conducted with untagged constructs.
PI 3-K(磷酸肌醇 3-激酶)催化亚基(p110)上的 NTT(N 端标签)先前已被证明可增加细胞信号转导和致癌转化。在这里,我们测试了 N 端(N 端)His 标签对所有 1 类 PI 3-K 同工型和两种代表性致癌突变体形式(E545K 和 H1047R)的体外脂质和蛋白激酶活性的影响,以阐明体内观察到这种增强的信号转导和转化背后的机制。我们的结果表明,NT His 标签对通过酶滴定、动力学和抑制剂敏感性测量的脂质激酶活性没有影响。相反,NT His 标签确实对蛋白激酶活性产生了差异影响,进一步增强了螺旋结构域和催化结构域致癌突变体的蛋白激酶活性,与 p110 磷酸化有关。所有其他同工型也显示出 p110 磷酸化增加(尽管没有统计学意义)。我们得出结论,先前报道的 p110 NTT 增加细胞信号转导和致癌样转化不是通过 PI 3-K 的脂质激酶活性增加介导的,但可能是通过增加 p110 自身磷酸化和/或其他尚未确定的细胞内蛋白/蛋白相互作用介导的。我们进一步观察到,标记的重组蛋白适合用于体外脂质激酶筛选以鉴定 PI 3-K 抑制剂;然而,我们建议对体内(包括细胞内)实验和 PI 3-K 的蛋白激酶活性进行研究应使用未标记的构建体进行。